vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) quickly fell 4% amid a report about the Federal Trade Commission’s review of its sale to AbbVie. The staff of the FTC’s Mergers 1 section is said to be apparently considering a recommendation to block the Cerevel (CERE) deal, according to aContinue Reading
sergeyryzhov/iStock via Getty Images Cerevel Therapeutics (NASDAQ:CERE) rose 2.2% amid a report that the Federal Trade Commission’s closed door meeting on Monday is about Tempur Sealy’s (NYSE:TPX) proposed acquisition of Mattress Firm. Tempur Sealy ticked down 0.5%. The FTC closed-door meeting is expected to decide the fate of the MattressContinue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) fell 5.5% as investors wait to hear if the Federal Trade Commission will approve its planned $8.7 billion sale to AbbVie (NYSE:ABBV). The deal spread is the widest since the transaction was announced in early December. While there was no specific reasonContinue Reading
